BridgeBio Pharma BBIO Prepaid & Other Current
Prepaid & Other Current at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's prepaid & other current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's prepaid & other current?
- BridgeBio Pharma (BBIO) reported prepaid & other current of $62.91M in Q1 2026.
- How has BridgeBio Pharma's prepaid & other current changed year-over-year?
- BridgeBio Pharma's prepaid & other current increased by 77.9% year-over-year, from $35.36M to $62.91M.
- What is the long-term trend for BridgeBio Pharma's prepaid & other current?
- Over 4 years (2021 to 2025), BridgeBio Pharma's prepaid & other current has grown at a 13.3% compound annual growth rate (CAGR), from $116.4M to $192.06M.
- What does prepaid & other current mean?
- Payments made for future services or other assets expected to be used within one year.
- How do you interpret prepaid & other current?
- Significant fluctuations may indicate changes in the scale of operational commitments or timing of large service contracts.
- How does prepaid & other current compare across companies?
- Generally consistent across peer companies as a percentage of operating expenses.